NASDAQ:FENC Fennec Pharmaceuticals (FENC) Stock Forecast, Price & News $8.63 +0.01 (+0.12%) (As of 05:16 PM ET) Add Compare Share Share Today's Range$8.47▼$8.8450-Day Range$7.27▼$9.0052-Week Range$5.26▼$10.85Volume81,569 shsAverage Volume90,785 shsMarket Capitalization$228.52 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Fennec Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside82.6% Upside$15.50 Price TargetShort InterestBearish6.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 2 Articles This WeekInsider TradingSelling Shares$12,939 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.50) to $0.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.73 out of 5 starsMedical Sector818th out of 986 stocksBiological Products, Except Diagnostic Industry133rd out of 163 stocks 3.5 Analyst's Opinion Consensus RatingFennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.50, Fennec Pharmaceuticals has a forecasted upside of 82.6% from its current price of $8.49.Amount of Analyst CoverageFennec Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.73% of the float of Fennec Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverFennec Pharmaceuticals has a short interest ratio ("days to cover") of 17, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldFennec Pharmaceuticals does not currently pay a dividend.Dividend GrowthFennec Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FENC. Previous Next 1.3 News and Social Media Coverage News SentimentFennec Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Fennec Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for FENC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fennec Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,939.00 in company stock.Percentage Held by Insiders11.25% of the stock of Fennec Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.34% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fennec Pharmaceuticals are expected to grow in the coming year, from ($0.50) to $0.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fennec Pharmaceuticals is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fennec Pharmaceuticals is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Fennec Pharmaceuticals (NASDAQ:FENC) StockFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Read More Receive FENC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address FENC Stock News HeadlinesJune 8, 2023 | finance.yahoo.comRetail investors who hold 38% of Fennec Pharmaceuticals Inc. (NASDAQ:FENC) gained 13%, institutions profited as wellJune 6, 2023 | finance.yahoo.comFennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology PatientsJune 9, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 21, 2023 | americanbankingnews.comChris A. Rallis Sells 1,758 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) StockMay 19, 2023 | americanbankingnews.comFY2023 EPS Estimates for Fennec Pharmaceuticals Inc (NASDAQ:FENC) Lowered by Cantor FitzgeraldMay 17, 2023 | insidermonkey.comFennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2023 Earnings Call TranscriptMay 17, 2023 | americanbankingnews.comEquities Analysts Offer Predictions for Fennec Pharmaceuticals Inc's FY2027 Earnings (NASDAQ:FENC)May 16, 2023 | americanbankingnews.comFennec Pharmaceuticals Inc to Post FY2027 Earnings of $2.68 Per Share, Capital One Financial Forecasts (NASDAQ:FENC)June 9, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 12, 2023 | markets.businessinsider.comMaxim Group Sticks to Its Buy Rating for Fennec Pharmaceuticals (FENC)May 11, 2023 | finanznachrichten.deFennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business UpdateMay 11, 2023 | msn.comRecap: Fennec Pharmaceuticals Q1 EarningsMay 11, 2023 | finance.yahoo.comFennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business UpdateMay 10, 2023 | investing.comFennec Pharma (FRX) Earnings Dates & ReportsMay 10, 2023 | msn.comEarnings Outlook For Fennec PharmaceuticalsMay 2, 2023 | americanbankingnews.comCantor Fitzgerald Brokers Boost Earnings Estimates for Fennec Pharmaceuticals Inc (NASDAQ:FENC)April 27, 2023 | theglobeandmail.comClosing Bell: Fennec Pharmaceuticals Inc flat on Wednesday (FRX)April 26, 2023 | theglobeandmail.comClosing Bell: Fennec Pharmaceuticals Inc flat on Tuesday (FRX)April 13, 2023 | bizjournals.comCipla seeks to dismiss RTP drugmaker's patent lawsuitApril 9, 2023 | americanbankingnews.comCantor Fitzgerald Boosts Fennec Pharmaceuticals (NASDAQ:FENC) Price Target to $16.00April 8, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Fennec Pharmaceuticals Inc Lowered by HC Wainwright (NASDAQ:FENC)April 7, 2023 | msn.comCantor Fitzgerald Maintains Fennec Pharmaceuticals (FENC) Overweight RecommendationApril 6, 2023 | markets.businessinsider.comAnalyst Ratings for Fennec PharmaceuticalsApril 5, 2023 | americanbankingnews.comFY2024 EPS Estimates for Fennec Pharmaceuticals Inc (NASDAQ:FENC) Cut by AnalystApril 5, 2023 | americanbankingnews.comResearch Analysts Issue Forecasts for Fennec Pharmaceuticals Inc's Q1 2024 Earnings (NASDAQ:FENC)April 5, 2023 | msn.comHC Wainwright & Co. Reiterates Fennec Pharmaceuticals (FENC) Buy RecommendationApril 4, 2023 | americanbankingnews.comFY2026 EPS Estimates for Fennec Pharmaceuticals Inc (NASDAQ:FENC) Reduced by AnalystSee More Headlines FENC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FENC Company Calendar Last Earnings5/11/2023Today6/09/2023Next Earnings (Estimated)8/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FENC CUSIPN/A CIK1211583 Webwww.fennecpharma.com Phone919-636-4530Fax919-890-0490EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$15.50 High Stock Price Forecast$19.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+79.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,710,000.00 Net MarginsN/A Pretax Margin-1,554.56% Return on Equity-7,266.90% Return on Assets-110.06% Debt Debt-to-Equity Ratio8.81 Current Ratio5.39 Quick Ratio5.16 Sales & Book Value Annual Sales$1.53 million Price / Sales149.71 Cash FlowN/A Price / Cash FlowN/A Book Value($0.10) per share Price / Book-86.50Miscellaneous Outstanding Shares26,480,000Free Float23,501,000Market Cap$229.05 million OptionableOptionable Beta0.17 Key ExecutivesMr. Rostislav Raykov (Age 42)Pres, CEO & Director Mr. Robert C. Andrade (Age 43)Chief Financial Officer Mr. Mark GowlandControllerMr. Lei FangPres of Pharstat IncMs. Anne McKay (Age 64)Regulatory Consultant Key CompetitorsGenfitNASDAQ:GNFTSangamo TherapeuticsNASDAQ:SGMOMolecular PartnersNASDAQ:MOLNAcumen PharmaceuticalsNASDAQ:ABOSInnate PharmaNASDAQ:IPHAView All CompetitorsInsiders & InstitutionsChris A RallisSold 1,758 sharesTotal: $12,938.88 ($7.36/share)Solas Capital Management LLCBought 32,155 shares on 5/16/2023Ownership: 4.863%Jane Street Group LLCBought 62,374 shares on 5/16/2023Ownership: 0.334%Susquehanna International Group LLPBought 14,000 shares on 5/16/2023Ownership: 0.000%Squarepoint Ops LLCBought 20,393 shares on 5/16/2023Ownership: 0.077%View All Insider TransactionsView All Institutional Transactions FENC Stock - Frequently Asked Questions Should I buy or sell Fennec Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FENC shares. View FENC analyst ratings or view top-rated stocks. What is Fennec Pharmaceuticals' stock price forecast for 2023? 5 Wall Street research analysts have issued 1 year price objectives for Fennec Pharmaceuticals' shares. Their FENC share price forecasts range from $11.00 to $19.00. On average, they anticipate the company's share price to reach $15.50 in the next year. This suggests a possible upside of 79.2% from the stock's current price. View analysts price targets for FENC or view top-rated stocks among Wall Street analysts. How have FENC shares performed in 2023? Fennec Pharmaceuticals' stock was trading at $9.60 on January 1st, 2023. Since then, FENC shares have decreased by 9.9% and is now trading at $8.65. View the best growth stocks for 2023 here. When is Fennec Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023. View our FENC earnings forecast. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc (NASDAQ:FENC) posted its quarterly earnings data on Thursday, May, 11th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.02. The company had revenue of $1.68 million for the quarter, compared to analysts' expectations of $1.88 million. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL). What is Fennec Pharmaceuticals' stock symbol? Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC." Who are Fennec Pharmaceuticals' major shareholders? Fennec Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Solas Capital Management LLC (4.86%), DG Capital Management LLC (4.73%), Harbert Fund Advisors Inc. (1.77%), Gendell Jeffrey L (0.96%), AIGH Capital Management LLC (0.61%) and Tamarack Advisers LP (0.56%). Insiders that own company stock include Chris A Rallis, Robert Andrade and Rosty Raykov. View institutional ownership trends. How do I buy shares of Fennec Pharmaceuticals? Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Fennec Pharmaceuticals' stock price today? One share of FENC stock can currently be purchased for approximately $8.65. How much money does Fennec Pharmaceuticals make? Fennec Pharmaceuticals (NASDAQ:FENC) has a market capitalization of $229.05 million and generates $1.53 million in revenue each year. The company earns $-23,710,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. How can I contact Fennec Pharmaceuticals? Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The official website for the company is www.fennecpharma.com. The company can be reached via phone at 919-636-4530 or via fax at 919-890-0490. This page (NASDAQ:FENC) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.